412 related articles for article (PubMed ID: 29211306)
1. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.
Schwaederle M; Krishnamurthy N; Daniels GA; Piccioni DE; Kesari S; Fanta PT; Schwab RB; Patel SP; Parker BA; Kurzrock R
Cancer; 2018 Mar; 124(6):1288-1296. PubMed ID: 29211306
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
[TBL] [Abstract][Full Text] [Related]
3. TERT promoter mutations are associated with poor prognosis and cell immortalization in meningioma.
Spiegl-Kreinecker S; Lötsch D; Neumayer K; Kastler L; Gojo J; Pirker C; Pichler J; Weis S; Kumar R; Webersinke G; Gruber A; Berger W
Neuro Oncol; 2018 Nov; 20(12):1584-1593. PubMed ID: 30010853
[TBL] [Abstract][Full Text] [Related]
4. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.
Huang DS; Wang Z; He XJ; Diplas BH; Yang R; Killela PJ; Meng Q; Ye ZY; Wang W; Jiang XT; Xu L; He XL; Zhao ZS; Xu WJ; Wang HJ; Ma YY; Xia YJ; Li L; Zhang RX; Jin T; Zhao ZK; Xu J; Yu S; Wu F; Liang J; Wang S; Jiao Y; Yan H; Tao HQ
Eur J Cancer; 2015 May; 51(8):969-76. PubMed ID: 25843513
[TBL] [Abstract][Full Text] [Related]
5. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas.
Li Y; Cheng HS; Chng WJ; Tergaonkar V
Proc Natl Acad Sci U S A; 2016 Dec; 113(50):14402-14407. PubMed ID: 27911794
[TBL] [Abstract][Full Text] [Related]
6.
Bai X; Kong Y; Chi Z; Sheng X; Cui C; Wang X; Mao L; Tang B; Li S; Lian B; Yan X; Zhou L; Dai J; Guo J; Si L
Clin Cancer Res; 2017 Oct; 23(20):6120-6127. PubMed ID: 28720667
[No Abstract] [Full Text] [Related]
7. Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup.
Pirker C; Bilecz A; Grusch M; Mohr T; Heidenreich B; Laszlo V; Stockhammer P; Lötsch-Gojo D; Gojo J; Gabler L; Spiegl-Kreinecker S; Dome B; Steindl A; Klikovits T; Hoda MA; Jakopovic M; Samarzija M; Mohorcic K; Kern I; Kiesel B; Brcic L; Oberndorfer F; Müllauer L; Klepetko W; Schmidt WM; Kumar R; Hegedus B; Berger W
Clin Cancer Res; 2020 Jul; 26(14):3819-3830. PubMed ID: 32317288
[TBL] [Abstract][Full Text] [Related]
8. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
[TBL] [Abstract][Full Text] [Related]
9. TERT promoter mutations lead to high transcriptional activity under hypoxia and temozolomide treatment and predict poor prognosis in gliomas.
Chen C; Han S; Meng L; Li Z; Zhang X; Wu A
PLoS One; 2014; 9(6):e100297. PubMed ID: 24937153
[TBL] [Abstract][Full Text] [Related]
10. Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness.
Macerola E; Loggini B; Giannini R; Garavello G; Giordano M; Proietti A; Niccoli C; Basolo F; Fontanini G
Virchows Arch; 2015 Aug; 467(2):177-84. PubMed ID: 26055532
[TBL] [Abstract][Full Text] [Related]
11.
Colebatch AJ; Dobrovic A; Cooper WA
J Clin Pathol; 2019 Apr; 72(4):281-284. PubMed ID: 30696697
[TBL] [Abstract][Full Text] [Related]
12. Discriminating association of a common telomerase reverse transcriptase promoter polymorphism with telomere parameters in non-small cell lung cancer with or without epidermal growth factor receptor mutation.
Yuan P; Huang S; Bao FC; Cao JL; Sheng HX; Shi L; Lv W; Hu J
Eur J Cancer; 2019 Oct; 120():10-19. PubMed ID: 31446212
[TBL] [Abstract][Full Text] [Related]
13. Androgen Receptor Enhances Hepatic Telomerase Reverse Transcriptase Gene Transcription After Hepatitis B Virus Integration or Point Mutation in Promoter Region.
Li CL; Li CY; Lin YY; Ho MC; Chen DS; Chen PJ; Yeh SH
Hepatology; 2019 Feb; 69(2):498-512. PubMed ID: 30070724
[TBL] [Abstract][Full Text] [Related]
14. TERT promoter mutations in primary and secondary glioblastomas.
Nonoguchi N; Ohta T; Oh JE; Kim YH; Kleihues P; Ohgaki H
Acta Neuropathol; 2013 Dec; 126(6):931-7. PubMed ID: 23955565
[TBL] [Abstract][Full Text] [Related]
15.
Yu Y; Fan D; Song X; Zakeri K; Chen L; Kang J; McBride S; Tsai CJ; Dunn L; Sherman E; Katabi N; Dogan S; Cracchiolo J; Cohen M; Boyle JO; Lee M; Valero C; Wang J; Wong R; Morris L; Riaz N; Lee N
JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34381934
[TBL] [Abstract][Full Text] [Related]
16. Frequent somatic mutations of the telomerase reverse transcriptase promoter in ovarian clear cell carcinoma but not in other major types of gynaecological malignancy.
Wu RC; Ayhan A; Maeda D; Kim KR; Clarke BA; Shaw P; Chui MH; Rosen B; Shih IeM; Wang TL
J Pathol; 2014 Mar; 232(4):473-81. PubMed ID: 24338723
[TBL] [Abstract][Full Text] [Related]
17. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
[TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
[TBL] [Abstract][Full Text] [Related]
19. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
Griewank KG; Murali R; Puig-Butille JA; Schilling B; Livingstone E; Potrony M; Carrera C; Schimming T; Möller I; Schwamborn M; Sucker A; Hillen U; Badenas C; Malvehy J; Zimmer L; Scherag A; Puig S; Schadendorf D
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25217772
[TBL] [Abstract][Full Text] [Related]
20. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D; Yildiz G; Ozturk M
World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
